International application No. PCT/SE 2004/000635

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07D 277/64, C07D 417/12, C07D 235/08, C07D 235/10, C07D 277/68, C07D 263/56, A61K 31/4184, A61K 31/5377, A6IP 25/04, A6IP 25/28 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D, A61K, A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CHEM.ABS.DATA, WPI DATA, EPO-INTERNAL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E,X	WO 2004056774 A2 (NEUROGEN CORPORATION), 8 July 2004 (08.07.2004)	1-18
·		
Ρ,Χ	WO 03037274 A2 (ICAGEN, INC.), 8 May 2003 (08.05.2003)	1,2,5-7, 9-16,18
	 .	
Ρ,χ	WO 2004011440 A1 (BANYU PHARMACEUTICAL CO., LTD), 5 February 2004 (05.02.2004)	1,6
		
}		

LX	Further documents are listed in the continuation of Box	C .	X s	ee patent family annex.		
	Special categories of cited documents:	"T"				
"A"	document defining the general state of the art which is not considered to be of particular relevance	1	uate and n	ment published after the international filing date or priority ot in conflict with the application but cited to understand ale or theory underlying the invention		
"E"	earlier application or patent but published on or after the international filing date	"X"	document	of particular relevance: the claimed invention connect he		
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other-		considered novel or cannot be considered to involve an step when the document is taken alone			
1	special reason (as specifica)	"Y"	document	of particular relevance: the claimed invention cannot be		
″0″	document referring to an oral disclosure, use, exhibition or other means		combined	with one or more other such documents, such combination		
P	document published prior to the international filing date but later than the priority date claimed	* B.*	nering open	ous to a person skilled in the art		
Date				member of the same patent family		
Date	e of the actual completion of the international search	Date	of mailing	of the international search report		
20	20 Sept 2004		_			
<u></u>			2	1 -09- 2004		
Nam	Name and mailing address of the ISA/		Authorized officer			
Swe	Swedish Patent Office					
	Box 5055, S-102 42 STOCKHOLM		ANNA SJÖLUND/BS			
	Facsimile No. + 46 8 666 02 86					
		Telephone No. + 46 8 782 25 00				
Form	PCT/ISA/210 (second sheet) (January 2004)					

Form PCT/ISA/210 (second sheet) (January 2004)

International application No.
PCT/SE 2004/000635

Categori*	Citation of document with indication when	
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim N
X .	STN International, File REGISTRY, see RN: 627074-44-6, 626202-75-3, 540516-48-1, 503429-34-3, 498535-73-2, 497247-81-1, 497242-15-6, 489464-52-0, 477554-52-2, 477506-36-8, 392251-13-7, 391223-69-1, 372081-90-8, 338431-35-9, 335397-26-7, 335397-24-5, 330567-86-7, 330189-20-3, 314027-99-1, 313500-75-3, 300572-54-7, 300572-47-8, 497240-67-2, 477554-53-3, 477492-97-0, 476284-34-1, 391218-49-8, 381696-06-6, 335397-25-6, 330189-19-0, 313959-23-8, 293766-14-0, January 2001	1-3,5-7
x	STN International, file ACS, ACS accession no. 132:265201, Suzuki, Nobuhiro; Takekawa, Shiro; Kubo, Keiji; Imaeda, Yasuhiro (Takeda Chemical Industries, Ltd., "Preparation of imidazole derivatives as gonadotropinreleasing hormone antagonists", & JP,A2,2000095767,20000404, 79 pp. CAS RN: 263022-44-2	1-12,16
x	STN International, file ACS, ACS accession no. 1999:626041, document no. 131:257447, Shinkai, Hisashi; Ito, Takao; Yamada, Hideki (Japan Tobacco Inc., Japan), "Preparation of amide derivatives as nociception antagonists", & WO,A1,9948492,19990930, 113 pp. CAS RN: 244219-85-0	1-12,16
x	WO 03014064 A1 (BAYER AKTIENGESELLSCHAFT), 20 February 2003 (20.02.2003)	1-17
K	US 3711608 A (CAMPBELL), 16 January 1973 (16.01.1973)	1-16
K	WO 0242273 A2 (BRISTOL-MYERS SQUIBB COMPANY), 30 May 2002 (30.05.2002), ex. 175,178,181	1-17

International application No.
PCT/SE 2004/000635

	PC1/3E 200	7/000033
C (Continu	ation). DOCUMENTS CONSIDERED TO BE RELEVANT	
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim
X	STN International, file CAPLUS, CAPLUS accession no. 1986:472101, document no. 105:72101, Miller, Robert E.; Reid Willis, A., Jr.(Dep. Parasitol., Walter Reed Army Inst. Res., Washington, DC, 20307, USA), "Schistosoma mansoni: salicylanilides as topical prophylactic against cercarial penetration of mice" & Experimental Parasitology, 61(3), 359-68, (English) 1956, CAS RN: 98290-34-7	1,6,9-11
x	STN International, file CAPLUS, CAPLUS accession no. 1981:444733, document no. 95:444733, Frey, Christoph (Ciba-Geigy A.G., Switz). "Iminoisoindolinone metal complexes, method for pigmenting an organic high-molecular-weight material and high-molecular-weight organic material containing such a metal complex", & EP,23889,19810211	1,6
		
	•	
	·	
	}	
	·	
-		
n PCT/ISA	210 (continuation of second sheet) (January 2004)	

International application No.
PCT/SE 2004/000635

Bo	x No.	II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
Th	is inte	rnational search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1.	\boxtimes	Claims Nos.: 18 because they relate to subject matter not required to be searched by this Authority, namely: see extra sheet
2.	\boxtimes	Claims Nos.: 1-2, 4-5, 7 because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically: see extra sheet
3.		Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Bo	x No.	III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
Th	is Inte	rnational Searching Authority found multiple inventions in this international application, as follows:
	see	extra sheet
		·
1.		As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.	\Box	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.		As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.	⊠	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-17
Rei	nark (The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

Box II.1

Claim 18 relates to methods of treatment of the human or animal body by surgery or by therapy or diagnostic methods practiced on the human or animal body (Rule 39.1(iv)). Nevertheless, a search has been executed for this claim. The search has been based on the alleged effects of the compounds or compositions

Box II.2

The initial phase of the search revealed a very large number of documents relevant to the issue of novelty. So many documents were retrieved that it is impossible to determine which parts of the claims 1-2, 4-5, 7 may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT). For these reasons, a meaningful search over the whole breadth of the claims is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds mentioned in claim 8, with due regard to the general idea underlying the present invention.

Present claim 12 relates to the treatment of diseases which are actually not well defined. The use of the definition "VR1 mediated disorders" in the present context is considered to lead to a lack of clarity within the meaning of Article 6 PCT. The lack of clarity is such as to render a meaningful search not fully possible.

Consequently, the search has been restricted to the parts relating to the diseases mentioned in claims in claims 13-18 with due regard to the general idea underlying the present invention.

Box III

The International Search Authority considers that there are 2 inventions covered by the claims indicated as follows:

I: Claims: 1-17, directed to compounds of formula I, compositions and uses thereof.

II: Claims 19-20, directed to intermediate compounds, and uses thereof in the preparation of the compound of formula I.

Information on patent family members

03/09/2004

International application No. PCT/SE 2004/000635

WO	2004056774	A2	08/07/2004	NOI	NE	•
WO .	03037274	A2	08/05/2003	CA	2465207 A	08/05/2003
WO	2004011440	A1	05/02/2004	NO	NE	**************************************
WO	03014064	A1	20/02/2003	CA JP	2455754 A 2003055209 A	20/02/2003 26/02/2003
US	3711608	Α	16/01/1973	FR	2132894 A,B	24/11/1972
WO	0242273	A2	30/05/2002	AU CA CA EP HU UP US US US WO	2726902 A 3123502 A 2426716 A 2428191 A 1332129 A 1332131 A 0303901 A 0400651 A 2004514669 T 2004517060 T 6642252 B 6713467 B 20020151545 A 20030166685 A 20040077865 A 0237937 A	03/06/2002 21/05/2002 16/05/2002 30/05/2002 06/08/2003 06/08/2004 28/06/2004 20/05/2004 10/06/2004 04/11/2003 30/03/2004 17/10/2002 04/09/2003 22/04/2004 16/05/2002

Form PCT/ISA/210 (patent family annex) (January 2004)